S T THURAISINGHAM, and P M SCHOFIELD (Papworth Hospital, Cambridge CB3 8RE) write: Papaverine administered by the intracoronary route in humans produces a brief maximal hyperaemic response in the coronary circulation that has little systemic effect and is used to measure coronary flow reserve in cardiac disease. 2 Intracoronary papaverine is known to produce changes in cardiac electrophysiological variables and ST-T configuration and prolongation of the QT interval.3 Isolated cases of ventricular tachycardia and ventricular fibrillation have also been described. 46 We describe a case of complete atrioventricular block after intracoronary papaverine administration.
A 53 year old man was undergoing investigations for chest pain with a positive response on exercise electrocardiography and normal coronary arteries on angiography. He was readmitted for further investigations, including coronary flow reserve studies. He had been taking nifedipine for several months and this was stopped 24 hours before cardiac catheterisation. His only other medication was dipyridamole, which was continued. A 45 year old man had a seven year history of heavy drinking (100 units per week) and mild late onset asthma. Twice when intoxicated his blood pressure had measured 180/100 mmHg. Before starting disulfiram 200 mg/day his blood pressure was normal. On the sixth day of the loading dose he was challenged with three doses of 100 ml of lager (alcohol 4-1% vol) administered at 0, 10, and 20 minutes. Before the challenge his blood pressure was 140/100 mm Hg. His pulse, respiratory rate, and findings on chest examination were normal. After the third dose the patient complained of lightheadedness and facial flushing. His blood pressure rose to 160/ 1 15 mm Hg and during the next 10 minutes reached 270/150 mm Hg. The heart rate was 100 beats/min with moderate dyspnoea and widespread wheezing. Blood pressure began to fall within five minutes but bronchospasm required two inhalations of salbutamol. Clinical signs returned to normal within 30 minutes, and no further adverse effects were detected during the following eight hours.
Bronchoconstriction during a disulfiram-ethanol reaction has not been reported before, though the Committee on Safety of Medicines has had two reports of bronchospasm with disulfiram. Apart from one case complicated by coma, meningitis, acute pulmonary oedema, and cerebromeningeal oedema,l hypertension has also not been reported during these circumstances. There has been one report of disulfiram causing moderate hypertension in an abstinent man taking therapeutic doses and another of slightly raised blood pressure in normal people and alcohol misusers receiving high doses of disulfiram.2 ' In our patient the paroxysmal onset of the symptoms, the interval between challenge and the simultaneous development of hypertension and asthma, the duration of the clinical manifestations, and their resolution all suggest a causal relation.
Severe hypertension and bronchoconstriction during a disulfiramethanol reaction are possible, the first in those with risk factors for hypertension other than alcohol, the second in patients with a history of bronchospasm. 
